Methods and compositions for synaphically-targeted treatment for cancer
Disclosed are compositions and methods useful for targeting therapeutics to cancerous cells and tumors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells and tumors.
1. A method of treating cancer, the method comprising:
administering to a subject having cancer a composition comprising a homing compound coupled to a paclitaxel-loaded albumin nanoparticle, wherein the homing compound is a LyP-1 peptide, wherein the subject is identified as having a cancer associated with gC1g/p32 receptor.
2. The method of claim 1 , wherein the composition further comprises a second homing compound coupled to the nanoparticle, wherein the second homing compound is a CREKA peptide.
3. The method of claim 1 further comprising administering to the subject a second composition comprising a second homing compound coupled to a paclitaxel-loaded albumin nanoparticle.
4. A method of identifying a subject as having a cancer associated with gC1q/p32 receptor, wherein the identification is accomplished by bringing into contact a cancer of the subject and a composition that selectively interacts with gC1q/p32 receptor; and
detecting interaction between gC1q/p32 receptor and the composition that selectively interacts with gC1q/p32 receptor, thereby detecting the presence or level of gC1q/p32, wherein the presence or level of gC1q/p32 receptor identifies the subject as having a cancer associated with a gC1q/p32 receptor.
5. The method of claim 4 , wherein the composition that selectively interacts with gC1q/p32 receptor is a LyP-1 composition, wherein the LyP-1 composition comprises a moiety linked to a LyP-1 peptide.
6. The method of claim 4 , wherein the level of the composition that selectively interacts with gC1q/p32 receptor interacting with gC1q/p32 receptor is detected.
7. The method of claim 4 , wherein the level of gC1q/p32 receptor in the subject is compared to a previous measurement in the same subject.
8. The method of claim 4 , wherein the level of gC1q/p32 receptor in the subject is compared to a control level or standard level.
9. The method of claim 5 , wherein the moiety is a detectable agent, a polypeptide, a nucleic acid molecule, or a small molecule.
10. The method of claim 4 , wherein the composition that selectively interacts with gC1q/p32 receptor comprises a virus.
11. The method of claim 4 , wherein the composition that selectively interacts with gC1q/p32 receptor comprises a phage.
12. The method of claim 9 , wherein the detectable agent is a radionuclide, a small molecule, a fluorophore, fluorescein, rhodamine, indium-111, technetium-99, carbon-11, carbon-13, or a combination thereof.
13. The method of claim 11 , wherein the LyP-1 peptide comprises SEQ ID NO:1, SEQ ID NO:13, or a variant of SEQ ID NO:1 or SEQ ID NO:13 with one or more conservative amino acid substitutions.
14. The method of claim 13 , wherein the LyP-1 peptide consists essentially of SEQ ID NO:1 or SEQ ID NO:13.
15. The method of claim 13 , wherein the LyP-1 peptide is SEQ ID NO:1, SEQ ID NO:13, or a variant of SEQ ID NO:1 or SEQ ID NO:13 with one or more conservative amino acid substitutions.
16. The method of claim 13 , wherein the LyP-1 peptide is SEQ ID NO:1 or SEQ ID NO:13.
17. The method of claim 1 , wherein the composition further comprises a therapeutic moiety.
18. The method of claim 17 , wherein the therapeutic moiety targets a DNA-associated process.
19. The method of claim 17 , wherein the therapeutic moiety is selected from the group consisting of a cytotoxic agent, an alkylating agent, an anti-tumor antibiotic, a sequence-selective agent, and an anti-angiogenic agent.
20. A composition comprising a homing compound coupled to a paclitaxel-loaded albumin nanoparticle, wherein the homing compound is a LyP-1 peptide.
21. The method of claim 19 , wherein the cytotoxic agent is selected from the group consisting of cyclophosphamide, melphalan, mitomycin C, bizelesin, cisplatin, doxorubicin, etoposide, mitoxantrone, SN-38, Et-743, actinomycin D, bleomycin, geldanamycin, chlorambucil, methotrexate, and TLK286.
22. The method of claim 13 , wherein the variant of SEQ ID NO:1 or SEQ ID NO:13 has one, two or three conservative amino acid substitution.
23. The method of claim 22 , wherein the variant of SEQ ID NO:1 or SEQ ID NO:13 has one conservative amino acid substitution.
24. The method of claim 1 , wherein the homing compound is a LyP-1 peptide, wherein the LyP-1 peptide comprises SEQ ID NO:1 or SEQ ID NO:13.
25. The method of claim 13 , wherein the variant of SEQ ID NO:1 comprises CANKRTRGC, CGDKRTRGC, CGNRRTRGC, CGNKKTRGC, CGNKRSRGC, CGNKRTKGC, or CGNKRTRAC.
26. The method of claim 13 , wherein the variant of SEQ ID NO:13 comprises CAQKRTRGC, CGQRRTRGC, CGQKKTRGC, CGQKRSRGC, CGQKRTKGC, or CGQKRTRAC.